FORTE BIOSCIENCES INC

Forte Biosciences is a clinical-stage biotechnology company developing therapeutic candidates for autoimmune and inflammatory diseases. Its primary drug candidate, FB-401, is a topical live biotherapeutic for atopic dermatitis. The development of such biologic pharmaceuticals typically requires extensive animal testing during preclinical stages to establish safety, efficacy, and dosing before human trials can begin. This standard industry practice constitutes commercial exploitation of animals under the firm's ethical screen.

While specific details of Forte's animal testing protocols are not publicly disclosed in its regulatory filings, the company's clinical development pathway inherently relies on animal models. Its 10-K filings reference the establishment of clinical endpoints and bioanalytical methods, processes that are predicated on successful animal studies. The company is flagged by Cruelty Free Investors, an organization that identifies firms engaged in animal testing, placing it among biotechnology companies that exploit animals for product development.